Intersect ENT (XENT) Gets a Hold Rating from Canaccord Genuity
Canaccord Genuity analyst Kyle Rose maintained a Hold rating on Intersect ENT (XENT) yesterday and set a price target of $18.00. The company’s shares closed last Monday at $15.96.
According to TipRanks.com, Rose is a 4-star analyst with an average return of 7.2% and a 48.0% success rate. Rose covers the Healthcare sector, focusing on stocks such as Zimmer Biomet Holdings, Smith & Nephew Snats, and SeaSpine Holdings.
The word on The Street in general, suggests a Hold analyst consensus rating for Intersect ENT with a $18.38 average price target, representing a 18.2% upside. In a report issued on October 22, Piper Sandler also maintained a Hold rating on the stock with a $16.00 price target.
See today’s analyst top recommended stocks >>
Based on Intersect ENT’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $9.78 million and GAAP net loss of $23.12 million. In comparison, last year the company earned revenue of $26.66 million and had a GAAP net loss of $11.38 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intersect ENT, Inc. is a commercial drug delivery company, which engages in the treatment of ear, nose, and throat conditions. Its products include PROPEL and SINUVA. The PROPEL used to maintain the opening and locally deliver steroid after sinus surgery. The SINUVA is used to treat adult patients with ethmoid sinus surgery yet suffer from recurrent sinus obstruction due to polyps. The company was founded by Donald J. Eaton in October 2003 and is headquartered in Menlo Park, CA.